ClinicalTrials.gg
Enrolling by invitationNCT07111416PRECISE DM DXUpdated Oct 29, 2026

Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis

An observational study in Type 2 Diabetes, sponsored by Brigham and Women's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Brigham and Women's Hospital · Observational

How we know

Updated Oct 29, 2026Now Enrolling by invitationFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital — 4 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Brigham and Women's Hospital.

Planned enrollment
24th of 24
45 · median 33,866
Started
2025
with 4 others
Observational
25 of 45
2 open now
Registered
40th of 45
by date

Among the 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital, this one is the 24th largest by planned enrollment of the 24 observational ones that give a count, is one of 5 that started in 2025, is one of 25 observational ones, and was the 40th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Diabetes Mellitus, Type 2 by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'.

The main question it aims to answer is:

Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population?

Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals 65 years of age and older, who have evidence of A1c-glucose discordance without either a diagnosis of type 2 diabetes or current/ prior treatment for type 2 diabetes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years of age or older
  • A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes
  • Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm
  • At least five (5) values and three (3) CBC values available in the EHR in the previous 10 years
  • Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days
  • Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities

Exclusion criteria

Exclusion Criteria:

  • Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
  • anemia based on most recent hematocrit (M = \<38%, F \<33%) and/or (M = \<12 g/dL, F = \<10 g/dL) within the last 12 months
  • Condition with short
  • Blood (hematologic)
  • rtCGM-interference agents per manufacturer (e.g., high dose vitamin C)
  • Unstable psychiatric or medical condition
  • Active treatment for cancer, planned treatment for cancer, or recent active cancer with a likelihood of recurrence or progression, that, in the opinion of the site investigator, would interfere with study therapy prior to 2029

    • Allowed Exceptions: Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy. Examples of allowable cancers include:

      • Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy
      • Prostate cancer being observed
      • Stage 0 or 1 tumors status post resection or other definitive treatment
      • Other similarly stable cancer comorbidities
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Calculate the Mean Absolute Difference Between A1c-Derived Estimated Average Glucose (eAG) and CGM-Derived eAG

    Determine the mean absolute difference between estimated average glucose (eAG) calculated from hemoglobin A1c and eAG derived from Continuous Glucose Monitoring (CGM) data. This measure will be assessed among participants suspected of having discordance between A1c values and actual blood glucose levels.

    Time frame: From 1 week after enrollment to the end of their enrollment at either week 5 or week 10

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 12 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Sep 2025 → Dec 2025, primary completion Apr 2026 → Dec 2026 and completion May 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Dec 1, 2025was Sep 2025
Primary completionEst.
Dec 1, 2026was Apr 2026
CompletionEst.
Mar 1, 2027was May 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 29, 2026
Sites
1 site added — first site in United States
Show site
  • Brigham and Women's Hospital · Boston, United States
Oct 29, 2026
Start date
Sep 1, 2025→Dec 1, 2025 (actual)
Oct 29, 2026
Primary completion
Apr 1, 2026→Dec 1, 2026
Oct 29, 2026
Study completion
May 1, 2026→Mar 1, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in United States
    Show site
    • Brigham and Women's Hospital · Boston, United States
    Start date Sep 1, 2025→Dec 1, 2025 (now actual)
    Primary completion Apr 1, 2026→Dec 1, 2026
    Study completion May 1, 2026→Mar 1, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07111416
Responsible party
Marie McDonnell (Associate Professor, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 8, 2025
Start date
Dec 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion